Gout, a painful form of inflammatory arthritis, is poised to become an even greater public health challenge in the coming decades. According to projections, the global prevalence of gout is expected to rise significantly over the next twenty-five years, driven by aging populations, rising obesity rates, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with the disease, while an alarming 44 million people have uric acid levels above the normal range, putting them at risk.
Current treatment options, primarily oral xanthine oxidase inhibitors, are effective for many but come with significant drawbacks. Approximately 3% to 5% of patients cannot tolerate these drugs, and they carry boxed warnings for cardiovascular risk. Other common side effects include severe gastrointestinal issues, kidney toxicity, and paradoxical flare-ups that discourage adherence. These limitations underscore an urgent unmet need for safer, better-tolerated therapies.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, believes it has a solution in XORLO™, a proprietary formulation of oxypurinol. By utilizing a liposomal delivery system, XORLO achieves high bioavailability and rapid absorption, allowing for effective uric acid reduction at substantially lower total daily doses. This approach aims to overcome the historically poor oral absorption of oxypurinol, minimizing toxic-level exposure and severe gastrointestinal side effects associated with high-dose traditional therapies. As a result, XORTX is positioning XORLO as a differentiated option for gout patients.
The company recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This trial is designed to characterize the pharmacokinetics and efficacy of XORLO, building on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol, the active ingredient, has already begun using XORTX’s proprietary synthetic pathway, and the company is now working toward commercial drug batches.
Regulatory progress is also underway. XORTX is working toward a new drug application submission for XORLO. The company has prepared a new Investigational New Drug (IND) application for submission to the FDA in the fourth quarter of 2026, outlining its clinical development plan. If the two-part clinical trial is successful, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while simultaneously engaging in pre-commercialization activities. The company is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
With gout prevalence on the rise and existing therapies often falling short due to tolerability issues, XORTX’s advancement of XORLO could represent a meaningful step forward. If successful, the drug may offer a better-tolerated alternative that improves adherence and outcomes for millions of sufferers. The content was originally published on Benzinga and is available on www.newmediawire.com.
